Yaoguang Huang

Shenyang, 110016, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Structure-Based Discovery of HS34: A Highly Selective and Orally Bioavailable CDK9 Inhibitor for Triple-Negative Breast Cancer.

Structure-Based Discovery of HS34: A Highly Selective and Orally Bioavailable CDK9 Inhibitor for Triple-Negative Breast Cancer.

Journal: Journal of medicinal chemistry

Published: March 12, 2026

Rational design and synthesis of flavonolactam derivatives as potent topo I inhibitors with antitumor activity.

Rational design and synthesis of flavonolactam derivatives as potent topo I inhibitors with antitumor activity.

Journal: European journal of medicinal chemistry

Published: February 04, 2026

Rational Design of Oxazolonylflavone Derivatives as Novel CDK4/9 Inhibitors with Potent Antitumor Efficacy and Oral Bioavailability.

Rational Design of Oxazolonylflavone Derivatives as Novel CDK4/9 Inhibitors with Potent Antitumor Efficacy and Oral Bioavailability.

Journal: Journal of medicinal chemistry

Published: December 18, 2025

Corrigendum to "Development and structure-activity relationship of tacrine derivatives as highly potent CDK2/9 inhibitors for the treatment of cancer" [Eur. J. Med. Chem. 242 (2022): 114701].

Corrigendum to "Development and structure-activity relationship of tacrine derivatives as highly potent CDK2/9 inhibitors for the treatment of cancer" [Eur. J. Med. Chem. 242 (2022): 114701].

Journal: European journal of medicinal chemistry

Published: July 21, 2025

Targeting cyclin-dependent kinases: From pocket specificity to drug selectivity.

Targeting cyclin-dependent kinases: From pocket specificity to drug selectivity.

Journal: European journal of medicinal chemistry

Published: March 01, 2024

The ADAM17 inhibitor ZLDI-8 sensitized hepatocellular carcinoma cells to sorafenib through Notch1-integrin β-talk.

The ADAM17 inhibitor ZLDI-8 sensitized hepatocellular carcinoma cells to sorafenib through Notch1-integrin β-talk.

Journal: Pharmacological research

Published: October 25, 2023

Discovery of novel harmine derivatives as GSK-3β/DYRK1A dual inhibitors for Alzheimer's disease treatment.

Discovery of novel harmine derivatives as GSK-3β/DYRK1A dual inhibitors for Alzheimer's disease treatment.

Journal: Archiv der Pharmazie

Published: July 26, 2023

Development and structure-activity relationship of tacrine derivatives as highly potent CDK2/9 inhibitors for the treatment of cancer.

Development and structure-activity relationship of tacrine derivatives as highly potent CDK2/9 inhibitors for the treatment of cancer.

Journal: European journal of medicinal chemistry

Published: June 29, 2022

Discovery of novel tacrine derivatives as potent antiproliferative agents with CDKs inhibitory property.

Discovery of novel tacrine derivatives as potent antiproliferative agents with CDKs inhibitory property.

Journal: Bioorganic chemistry

Published: April 14, 2022

Discovery of novel α-carboline derivatives as glycogen synthase kinase-3β inhibitors for the treatment of Alzheimer's disease.

Discovery of novel α-carboline derivatives as glycogen synthase kinase-3β inhibitors for the treatment of Alzheimer's disease.

Journal: Archiv der Pharmazie

Published: March 27, 2022

Discovery of novel benzofuro[3,2-b]quinoline derivatives as dual CDK2/Topo I inhibitors.

Discovery of novel benzofuro[3,2-b]quinoline derivatives as dual CDK2/Topo I inhibitors.

Journal: Bioorganic chemistry

Published: March 10, 2022

Discovery of novel β-carboline derivatives as selective AChE inhibitors with GSK-3β inhibitory property for the treatment of Alzheimer's disease.

Discovery of novel β-carboline derivatives as selective AChE inhibitors with GSK-3β inhibitory property for the treatment of Alzheimer's disease.

Journal: European journal of medicinal chemistry

Published: November 17, 2021

Showing 1-12 of 12

Last Updated: 09/26/2026